Brief: Star Combo Pharma Says HY Operating Loss Attributable A$4.4 Million
Feb 27 (Reuters) - Star Combo Pharma Ltd S66.AX :
* HY OPERATING LOSS ATTRIBUTABLE A$4.4 MILLION VERSUS LOSS
A$997
* HY REVENUE A$11.6 MILLION VERSUS A$11.8 MILLION
* BUSINESS STRATEGY IN FY23 REMAINS FOCUSED ON GROWING ITS
CONTRACT MANUFACTURING OPERATIONS
Source text for Eikon: ID:nASX50xfbh
Further company coverage: S66.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Star Combo Pharma
See all newsBrief: Star Combo Pharma Announces Insurance Claim Settlement Of A$5 Million
Brief: Star Combo Pharma Says Outlook For FY2025 Is Positive
Brief: Star Combo Pharma Says HY Operating Loss Attributable A$4.4 Million
Brief: Star Combo Pharma Posts Q1 Fy23 Revenue Of A$6.55M
Australia's Star Combo Pharma plunges to record low on fire incident